BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.

Next Day Disclosure Return

Announcements and Notices - [Overseas Regulatory Announcement - Other]

Overseas Regulatory Announcement - Form 8-K

Announcements and Notices - [Share Scheme]

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

BeiGene (6160 HK)

Next Day Disclosure Return

Next Day Disclosure Return

Overseas Regulatory Announcement - Form 8-K

Grant Of Share Options And Restricted Share Units

Next Day Disclosure Return

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)